However, pH-sensitive CTLA-4 mAbs maintain their bioavailability that is not degraded by the lysosomal, recirculate to the Treg surface, reduce adverse immune events, and exert high anti-tumor efficacy in the TME [175]. Here, CTLA4 is linked to neoplasm.